ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries Ltd announced the release of a pledge of 20,00,000 equity shares held by its promoter, Mr. Hemal Mehta. This disclosure complies with SEBI regulations.
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.
Sudarshan Pharma Industries Ltd has filed its Annual Report for the Financial Year 2025-26 with the exchange, pursuant to SEBI Regulation 34.
Sudarshan Pharma Industries Ltd has issued the notice for its 18th Annual General Meeting, scheduled to be held on September 22, 2026, via video conferencing.
Promoters Hemal V Mehta and Sachin V Mehta have created a pledge on 13,200,000 equity shares of the company as security for a loan.
Sudarshan Pharma Industries Ltd allotted 48,11,730 equity shares upon conversion of FCCBs. The conversion value is approximately ₹14.25 Crore.
Sudarshan Pharma Industries reports on its specialty chemicals and pharmaceutical business, highlighting the turnaround of Ratna Lifescience and strategic vertical integration into API manufacturing and branded generics.
Sudarshan Pharma Industries Ltd will acquire 3,000 shares, representing a 30% stake, in Sudarshan Maven Pharma Private Limited. This strategic acquisition will make the entity a wholly-owned subsidiary.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹174.4 Cr (+20.0% YoY) and net profit of ₹5.6 Cr (+40.0% YoY) for Q1 FY27.
Promoter Hemal Vasantrai Mehta released a pledge of 20,00,000 shares of Sudarshan Pharma Industries Limited. The shares were previously encumbered for personal loan reasons.
Sudarshan Pharma Industries Ltd has scheduled a board meeting for August 12, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Sudarshan Pharma Industries Ltd submitted its quarterly shareholding pattern under Regulation 31. This periodic disclosure provides details on promoter and public equity ownership.
Sudarshan Pharma issued 90,00,000 equity shares to promoters Hemal Mehta and Sachin Mehta. The allotment and listing approval process for these shares is currently underway.
Promoter Hemal Vasantrai Mehta pledged 20,00,000 shares of Sudarshan Pharma Industries, representing 0.83% of equity. The pledge was created for personal loan requirements.
Sudarshan Pharma Industries Ltd announced voting results for a postal ballot. All resolutions, including the migration to the main board, were passed.
Sudarshan Pharma allotted 90 lakh equity shares upon conversion of 9 lakh warrants by promoters. This strengthens promoter holding and increases paid-up capital to Rs.24.97 Crore.
Sudarshan Pharma's Warrants Committee meeting postponed from 11 June to 12 June 2026. The delay is procedural and does not affect the underlying warrant conversion agenda.
Sudarshan Pharma incorporated a wholly-owned US subsidiary, Sudarshan Industries Inc. This expands its international footprint and customer base in the USA.
Sudarshan Pharma Industries scheduled a Warrants Committee meeting for June 11, 2026. The committee will consider converting warrants and allotting equity shares to applicants.
Sudarshan Pharma Industries promoter Mr. Hemal Vasantrai Mehta pledged 20,00,000 shares on June 3, 2026. This creation of encumbrance increases promoter leverage and overall risk profile.
Sudarshan Pharma re-submitted its audited FY26 financial results to address BSE discrepancies. The filing ensures regulatory compliance and provides corrected standalone and consolidated performance data.
Sudarshan Pharma Industries submitted its Annual Secretarial Compliance Report for FY2026. The report by a practicing company secretary confirms overall regulatory compliance with no material penalties.
Sudarshan Pharma Industries issued a postal ballot notice for shareholder voting on migration to the main board. Remote e-voting ends on June 24, 2026.
Sudarshan Pharma Industries revised its FCCB conversion rate to Rs.96.8441 per USD following updated RBI rates. The USD 20 million issue reflects a Rs.193.69 Crore value.
Sudarshan Pharma's board approved migrating its equity shares from BSE SME to the Main Board. It also plans to list on the NSE Main Board.
Sudarshan Pharma allotted ₹96 Crore worth of FCCBs due 2029. This capital infusion strengthens liquidity and provides a route for future equity conversion.
Sudarshan Pharma pre-poned its board meeting to May 21, 2026, to consider migrating from the BSE SME platform to the main boards of BSE and NSE.
Sudarshan Pharma Industries scheduled a board meeting for May 22, 2026. Directors will consider migrating equity shares from BSE SME to the Main Board.